While there is currently no cure for geographic atrophy, certain treatments, such as complement inhibitors, can help slow its progression by targeting immune system activity that damages the macula.

There is currently no cure for geographic atrophy (GA) – in other words, no effective therapy to entirely halt the disease process, restore vision or reverse the damage to the retina. Currently ...

CTx001 has previously received FDA IND clearance and will be evaluated in Opti-GAIN, a first-in-human Phase I/II clinical trial MUNICH, Jan. 8, 2026 /PRNewswire/ -- Complement Therapeutics GmbH (CTx), ...

Complement Therapeutics GmbH, a clinical-stage biotechnology company developing next-generation therapeutics for complement-mediated diseases, announced that the US Food and Drug Administration (FDA) ...

While pivotal research on therapies for neovascular age-related macular degeneration (nAMD) and geographic atrophy (GA) focused on one condition or the other, retina specialists commonly encounter ...

- Kriya is developing KRIYA-825 as a potential one-time gene therapy, delivered by suprachoroidal injection, expressing a fusion protein inhibiting the activity of complement C3 and C5 for the ...

New York, USA, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Geographic Atrophy Market to Surge Significantly During the Forecast Period (2025–2034) Due to Rising Adoption of Complement Inhibitor Therapies | ...

GA treatment market heats up: Syfovre & Izervay lead, while oral, gene, cell therapies and AI‐enabled tools enter, with global growth and supply challenges. Recent FDA approvals mark only the ...

To make an accurate diagnosis and initiate the correct treatment, geographic atrophy (GA) must be differentiated from similar diseases. The presence of well-defined lesions is the most distinct ...

LONG BEACH, Calif. -- Concomitant treatment with drugs for geographic atrophy (GA) and neovascular macular degeneration (nAMD) appeared to have no major safety issues or significantly affect either ...

DelveInsight’s Geographic Atrophy Market Insights report includes a comprehensive understanding of current treatment practices, emerging geographic atrophy drugs, market share of individual therapies, ...